Your body makes melatonin every night. It is secreted by your pineal gland in response to darkness. It is a hormone you produce naturally, that every human being produces naturally, as part of the fundamental biology of day and night. And it is on an EU priority restriction list.
Let me explain the concern fairly and then tell you why the proposed response is disproportionate.
The concern.
Melatonin is a hormone, and that is not a trivial distinction. The French food safety agency ANSES received more than 200 adverse effect reports associated with melatonin supplements in France including headache, dizziness, nausea, daytime drowsiness, and hormonal effects. ANSES recommended that certain populations avoid melatonin supplements: pregnant women, breastfeeding women, children, and people with autoimmune conditions, epilepsy, or asthma. France caps supplement melatonin at less than 2 milligrams per day.
The EU's HoA Working Group placed melatonin on its priority restriction list, citing concerns about its hormonal nature, the dose-dependency of its effects, and particular concerns about its use in children and adolescents where there are theoretical concerns about effects on pubertal development, though the evidence on this specific point is not conclusive.
These are not fabricated concerns. Melatonin is pharmacologically active. Dose matters. The timing of administration matters. Chronic use patterns matter. In children especially, where the endogenous melatonin system is still developing, caution is warranted.
**What the evidence actually shows **
For adults, the safety record of melatonin supplementation is extensive. In multiple clinical trials, melatonin has been found to be well tolerated and not associated with serum enzyme elevations or evidence of liver injury the NIH LiverTox database is clear on this. No hepatotoxicity signal exists for melatonin in the clinical literature.
The most common adverse effects are the ones you would expect from a sleep-inducing hormone: drowsiness, headache, dizziness, nausea. These are dose-dependent and they resolve on discontinuation. There is no evidence of organ toxicity, no genotoxicity signal, no cumulative harm at therapeutic doses in the adult literature.
Melatonin is effective. Systematic reviews and meta-analyses consistently confirm its efficacy for jet lag, delayed sleep-wake phase disorder, and some sleep disorders, particularly in children with neurodevelopmental conditions, where the evidence base is actually quite strong. But note: in the UK, melatonin is already classified as a Prescription Only Medicine. It is already not available as a food supplement here. Whatever the EU decides to do applies directly to other member states but via the SPS alignment and Windsor Framework dynamics, it creates real downstream regulatory pressure on UK trade and availability.
The drug interaction picture.
Melatonin may enhance the sedative effects of other CNS depressants. It may interact with anticoagulants — some data suggest it may modestly potentiate warfarin effects, though the evidence is inconsistent. It may affect immunosuppressant activity. These are real interactions that practitioners should know about and screen for. They are not justifications for prohibition.
Paracetamol, again.
The regulatory framework is restricting a molecule your own brain produces every night, at doses far below any demonstrated harm threshold in adults, on the basis of 200 adverse event reports and paediatric precautionary concerns that are already addressed by age-specific guidance.
Paracetamol causes approximately 56% of severe acute liver failure in UK specialist liver units. Approximately 47,500 people in England attend A&E annually for paracetamol-related harm. Paracetamol is in every corner shop. No restriction. No list.
What proportionate regulation looks like.
Age-specific guidance: melatonin supplements inappropriate for routine unsupervised use in children — already practitioner-supervised in the UK as a POM. Adult use: dose guidance, timing guidance, and drug interaction warnings on packaging. Practitioner involvement for anyone on anticoagulants or immunosuppressants. This is proportionate regulation that addresses the genuine concerns without prohibition.
The EU is proposing to restrict a molecule your body makes every night. The proportionate response to concerns about melatonin is adult dose guidance and paediatric age restrictions — not elimination from the supplement market.
The UK has committed to align food supplement law with EU restrictions under the SPS Agreement without a parliamentary vote. That commitment is public: www.gov.uk/government/news/uk-eu-sps-agreement-legislation-in-scope .
Sign the petition. Write to your MP at writetothem.com. Ask them: when Parliament did not vote on this, who gave their consent on your behalf?
#RightToHeal #HerbalAccessNI #SaveOurSupplements
